An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

Diabetes, Obesity and Metabolism

Volumn 12, Issue 6, 2010, Pages 495-509

  Ligueros Saylan, M ^a   Foley, J E ^a   Schweizer, A ^a   Couturier, A ^a   Kothny, W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dipeptidyl peptidase 4; Drug induced liver injury; Infections; Pancreatitis; Renal impairment; Skin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE HEPATITIS; ACUTE PANCREATITIS; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BACTERASCITES; BILE FLOW; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; BLISTER; CAPUT MEDUSAE; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHOLINESTERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; COLD SENSATION; CYTOLYTIC HEPATITIS; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DUODENUM VARICOSIS; EDEMA; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; EVENING DOSAGE; EXFOLIATIVE DERMATITIS; EYE JAUNDICE; FATTY LIVER; FIBRINOGEN BLOOD LEVEL; FLAPPING TREMOR; FOETOR HEPATICUS; GANGRENE; GLOMERULUS FILTRATION RATE; HEMORRHAGIC PANCREATITIS; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HEPATITIS; HEPATOBILIARY DISEASE; HEPATOCELLULAR FOAMY CELL SYNDROME; HEPATOMEGALY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HEPATOSPLENOMEGALY; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERCHOLIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; INFECTION; INFESTATION; INTERMITTENT CLAUDICATION; INTERNATIONAL NORMALIZED RATIO; IRIS DISEASE; JAUNDICE; KAYSER FLEISCHER RING; KIDNEY DYSFUNCTION; LIMB ISCHEMIA; LIMB PAIN; LIVER ATROPHY; LIVER BIOPSY; LIVER CALCIFICATION; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER CONGESTION; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER HYPERPLASIA; LIVER INJURY; LIVER ISCHEMIA; LIVER NECROSIS; LIVER PAIN; LIVER SARCOIDOSIS; LIVER SCINTISCANNING; LIVER SEQUESTRATION; LIVER TOXICITY; LIVER TUMOR; LIVER VASCULAR RESISTANCE; LOW DRUG DOSE; LUPUS HEPATITIS; META ANALYSIS; MICROANGIOPATHY; MORNING DOSAGE; NEVUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; PANCREAS ABSCESS; PANCREAS HEMORRHAGE; PANCREAS NECROSIS; PANCREAS PSEUDOCYST; PANCREATITIS; PERIPHERAL ISCHEMIA; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHLEGMON; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTOPULMONARY HYPERTENSION; PROTHROMBIN TIME; RADIATION HEPATITIS; RAYNAUD PHENOMENON; REYE SYNDROME; SIDE EFFECT; SKIN DEFECT; SKIN DISCOLORATION; SKIN DISEASE; SKIN EXFOLIATION; SKIN NECROSIS; SKIN PAIN; SKIN ULCER; SPIDER NEVUS; STOMACH VARICES; SYSTEMATIC REVIEW; THROMBIN TIME; THROMBOPHLEBITIS; ULCER; VARICOSIS; VASCULAR RESISTANCE; WOUND INFECTION;

EID: 77953192546     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01214.x     Document Type: Article

References (65)

1. Gupte P, Amarapurkar D, Agal S. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004, 19:854-858.
2. Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009, 29:113-119.
3. Lonardo A, Carulli N, Loria P. HCV and diabetes. A two-question-based reappraisal. Dig Liver Dis 2007, 39:753-761.
4. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009, 15:1537-1546.
5. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care 2009, 32:834-838.
6. Blomgren KB, Sundstrom A, Steineck G, Wiholm BE. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002, 25:298-302.
7. Fox CS, Coady S, Sorlie PD. Increasing cardiovascular disease burden to diabetes mellitus. Circulation 2007, 115:1544-1550. The Framingham Heart Study
8. Gerstein HC, Capes SE. Dysglycemia: a key cardiovascular risk factor. Semin Vasc Med 2002, 2:165-174.
9. He H, Yin H, Smith H. Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009, 37:536-544.
10. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
11. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, 1-131.
12. Hegen M, Kameoka J, Dong RP, Morimoto C, Schlossman SF. Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation. Adv Exp Med Biol 1997, 421:109-116.
13. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768.
14. Boonacker EP, Wierenga EA, Smits HH, Van Noorden CJF. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem 2002, 50:1169-1177.
15. Marguet D, Baggio L, Kobayashi T. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 2000, 97:6874-6879.
16. Galvus (vildagliptin) -European Public Assessment Report (EPAR) -scientific discussion. 2007, http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf, European Medicines Agency, Available from URL:, Accessed 30 September 2009.
17. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes 2009, 2:117-126.
18. 2006, Merck & Co, Inc. Januvia™, (sitagliptin) tablets., Whitehouse Station, NJ, Merck & Co., Inc.
19. Cox DR. The continuity correction. Biometrika 1970, 57:217-219.
20. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004, 23:1351-1375.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
22. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002, 22:169-183.
23. 2008, Merck & Co Inc. Zocor, tablets (Merck): (simvastatin)., Whitehouse Station, NJ, Merck & Co Inc.
24. Kothny W, Schweizer A, Dickinson S, Ligueros-Saylan M. Hepatic safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes (abstract 764). Diabetologia 2009, 52(Suppl. 1):S301.
25. Williams-Herman D, Round E, Swern AS. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008, 8:14.
26. Czako L, Hegyi P, Rakonczay Z, Wittmann T, Otsuki M. Interactions between the endocrine and exocrine pancreas and their clinical relevance. Pancreatology 2009, 9:359.
27. Bain SC, Stephens JW. Exenatide and pancreatitis: an update. Expert Opin Drug Saf 2008, 7:643-644.
28. Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010, 53:1-6.
29. Dimitrijevic M, Stanojevic S, Mitic K. The anti-inflammatory effect of neuropeptide y (NPY) in rats is dependent on dipeptidyl peptidase 4 (DP4) activity and age. Peptides 2008, 29:2179-2187.
30. Klemann C, Schade J, Pabst R. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leucocyte subsets in F344-rats age-dependently. Clin Exp Immunol 2009, 155:357-365.
31. Foley J, Hoffmann P, Ligueros-Saylan M, Schweizer A, Kothny W. Lack of vildagliptin effects on the immune system (abstract 773). Diabetologia 2009, 52(Suppl. 1):S304-S305.
32. Mentlein R. Dipeptidyl-peptidase IV (CD26) -role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
33. Byrd JB, Touzin K, Sile S. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008, 51:141-147.
34. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE-inhibitor-associated angioedema. Hypertension 2009, 54:516-523.
35. Lankas GR, Leiting B, Roy RS. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54:2988-2994.
36. Ansorge S, Bank U, Heimburg A. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009, 47:253-261.
37. Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008, 10:1057-1061.
38. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008, 68:2387-2409.
39. Dejager S, Baron MA, Schweizer A. DPP-4 inhibitors: review of vildagliptin phase 3 data. Rev Endocrinol 2007, 1:47-51.
40. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005, 7:692-698.
41. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006, 38:423-428.
42. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007, 39:218-223.
43. Scherbaum WA, Schweizer A, Mari A. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia. Diabetes Obes Metab 2008, 10:675-682.
44. Mari A, Scherbaum WA, Nilsson PM. Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008, 93:103-109.
45. Scherbaum WA, Schweizer A, Mari A. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10:1114-1124.
46. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naïve patients with type 2 diabetes. Diabet Med 2007, 24:955-961.
47. Goke B, Hershon K, Kerr D. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008, 40:892-895.
48. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 2009, 41:905-909.
49. Pan C, Yang W, Barona JP. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-441.
50. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9:166-174.
51. Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:571-578.
52. Rosenstock J, Foley JE, Rendell M. Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008, 31:30-35.
53. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138.
54. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009, 11:804-812.
55. Ferrannini E, Fonseca V, Zinman B. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11:157-166.
56. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30:890-893.
57. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008, 10:82-90.
58. Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009, 11:589-595.
59. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with Type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009, 41:368-373.
60. Blonde L, Dagogo-Jack S, Banerji MA. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial -a primary care, type 2 diabetes study. Diabetes Obes Metab 2009, 11:978-986.
61. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:506-515.
62. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:175-185.
63. Garber AJ, Foley JE, Banerji MA. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008, 10:1047-1056.
64. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
65. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008, 40:427-430.